Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Jun 1, 2008 (Vol. 28, No. 11)

PAT Initiative Helps Move HPLC Forward

Achieving the Speed, Reliability, and Robustness Firms Demand

  • Comparing Methods

    Amgen’s process-development group recently performed a feasibility study of HPLC to help guide fraction-pooling decisions during preparative liquid chromatography.

    Researcher Anurag Rathore, Ph.D., analyzed fractions from a hydroxyapatite column, comparing results by three methods: UV absorbance at 280 nm, an online DX-800 process analyzer from Dionex, and an offline reference system consisting of a TSK-GEL G3000 SWXL column from Tosoh Bioscience in an Agilent (www.agilent.com) 1100 LC system. The objective was to identify fractions containing undesirable amounts of protein dimers and other high molecular weight species.

    The three methods have their pluses and minuses. UV is simple and robust, but cannot differentiate among chemically distinct species absorbing at 280 nm. The offline reference analysis is accurate but time- and resource-inefficient. Online analysis was effective in the test separation, but its complexity raises issues for other applications.

    Dr. Rathore was able to tweak the online analysis method by increasing the HPLC flow rate while simultaneously slowing down elution from the preparative column. Analysis might be speeded up even more by switching to ultrahigh performance LC.

    One might ask at this point if real-time analysis is ever necessary in biotech. “That depends on the time scale of the unit operation,” Dr. Rathore says.

    For a cell culture, which may last weeks, the window for real-time analysis is long, on the order of hours, while for others, such as fraction pooling for preparative chromatography the real-time requirements, are much more apparent.

    In addition, the fact that chromatography always involves a retention time means that HPLC can never provide true real-time analysis as ultraviolet- or other spectrometric-detection methods can. “Bioprocessors rarely need to know what’s going on every second,” observes Ira Krull, Ph.D., professor at Northeastern University. Depending on the process, even rather slow HPLC can serve process engineers adequately.

  • One Answer: Column Technologies

    Craig Dobbs, senior pharmaceutical operations manager at Waters (www.waters.com), disagrees with the knock on real-time HPLC. He explains that, while spectroscopic detection is instantaneous, its associated data workup is not. When all factors are considered, he argues, a fast LC technique like Waters’ UltraPerformance LC (UPLC) may be time-equivalent to techniques like near-infrared, UV, and Raman, providing what amounts to real-time analysis.

    UPLC is a column or stationary-phase solution that achieves high speed without sacrificing resolution. Waters’ Patrol UPLC Process Analyzer uses sub-2 micron particles operating in the 12,000–15,000 psi pressure range while conventional HPLC runs at up to about 6,000 psi.

    Waters promotes UPLC as the first real advance in LC in 35 years.

    “You can run any conventional HPLC method on 35-year-old systems,” Dobbs says. “Instruments have become easier to use and more reliable and rugged, but the basic system hasn’t changed since 1972.”

    Data from UPLC experiments is impressive. For real-time analysis, UPLC does not demand a trade-off among resolution, sensitivity, and speed. UPLC routinely separates complex solutions in less than 30 seconds. “It makes real-time LC a reality,” notes Dobbs.

    He explains that while UV, Raman, and fluorescence operate in real time, deconvoluting the spectra takes several minutes. In that time most operators can perform one or more UPLC runs.

    Patrol UPLC’s standard online configuration enables fully automatic sampling from two independent process streams or sources. The system uses high-precision syringe drives for all sample and reagent metering to ensure accuracy throughout all phases of operation.

    Patrol is also available in an at-line configuration, which enables an operator to manually introduce a barcoded sample. The system reads the barcode; checks with the laboratory information management (LIMS) or distributed control system (DCS) software to confirm that the vial contains an appropriate sample for analysis; loads the appropriate analytical method, which includes column and buffer selection; begins the UPLC analysis; and, at the end, sends the data to the DCS or LIMS.

    Waters is currently collaborating with several pharmaceutical companies to quantify Patrol UPLC’s impact on manufacturing, with the goal of implementing it for real-time PAT.

    “Process HPLC differs from conventional analytical HPLC in the complexity of its samples, and often in its need for speed without sacrificing resolution or accuracy,” says Ales Strancar, Ph.D., CEO of BIA Separations (www.biaseparations.com).

    Process-level analysis is complicated by impurities, side products, additives, buffers, protein folding, and aggregation—most of which are gone by the time quality groups get hold of the product.

    BIA specializes in polymeric monolithic columns that satisfy process HPLC’s need for speed, versatility, high resolution, and ease of scale-up. Separations that take an hour with porous-particle stationary phases run in two minutes on a monolith. That is one reason these columns have become a hot topic at HPLC conferences.

    One exciting bioprocess application of monolithic columns is the analysis of vaccines, particularly virus-based products. Viruses and virus fragments tend to plug porous stationary phases, but not monoliths. A group in England is using BIA columns to separate viral particles from capsids and partially degraded viruses. According to Dr. Strancar these methods are suitable for process control and stability testing.

    The first vaccine purification using BIA’s CIM® monolithic columns took place in 2006. Other adopters include Novartis and Octapharma.

    Boehringer Ingelheim (www.boehringer-ingelheim.com) was reportedly the first company to use monolithic columns for the industrial cGMP purification of plasmid DNA, noting a 15-fold increase in productivity.

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »